Advertisement
MOUNTAIN VIEW, Calif. (AP) — MAP Pharmaceuticals Inc. has announced that its migraine treatment candidate met all of its main goals in a late-stage study, including a reduction in pain. The drug candidate, called Levadex, is aimed at relieving pain and other symptoms associated with migraines. The drug is being developed as an orally inhaled treatment.
Advertisement
Advertisement